Follicular Lymphoma Patients May Benefit From Combination Therapy

A high risk group of patients with follicular lymphoma may benefit from a novel drug combination, a new study has found

A high risk group of patients with follicular lymphoma may benefit from a novel drug combination, a new study has found.

Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Follicular lymphoma is characterized by slow and relentless tumor growth with inevitable relapses despite intense chemotherapy. Follicular lymphomas are driven by mutations that activate the BCL2 protein, which prevents cancer cells from dying, but additional genetic changes are also required. These could include mutations resulting in loss of cell cycle control, which is a hallmark of cancer and has a well-established role in aggressive B cell malignancies.

MRI Detects Breast Cancer Early in At-risk Survivors of Female Hodgkin Lymphoma
MRI scans detected invasive breast tumours at early stages in female survivors of Hodgkin lymphoma at an increased risk of breast cancer, a new study has found

To find out more, Hans-Guido Wendel and colleagues from Memorial Sloan-Kettering Cancer Center in New York analyzed genomic data from two large groups of slow-growing follicular lymphomas. The team identified a pattern of linked genetic mutations mainly in genes expressing cyclin-dependent kinases (CDKs), which impair the tumor-suppressing retinoblastoma (RB) pathway in nearly 50 percent of follicular lymphomas. The pathogenic role of these mutations was also confirmed in vivo in a mouse model of follicular lymphoma. Increased CDK4 activity is readily measured in tumor samples, and Wendel and colleagues show that a combination therapy of CDK4 and BCL2 inhibitors is safe and effective against available mouse models of follicular lymphoma.

About The Journal of Experimental Medicine
The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license.

Source-Newswise

Non-Hodgkin Lymphoma Gets Easier to Treat With a New Drug
With repeated relapse among patients and the disease becoming resistant to therapy, indolent and slow-growing non-Hodgkin lymphoma is now getting difficult to deal with

Frozen and Stored Semen Samples Increases Chances of Fatherhood for Male Victims of Hodgkin Lymphoma
Men with Hodgkin lymphoma who want to become fathers after their cancer treatment have greatly increased chances of doing so if they have frozen and stored semen samples beforehand,